Sou Hu Cai Jing·2026-02-26 13:47Core Viewpoint - The Hong Kong pharmaceutical sector experienced a significant adjustment, with innovative drugs and CXO sectors leading the decline, reflecting a valuation restructuring logic during the industry's high-quality development transition [1][2]. Group 1: Market Performance - Over 60% of the 290 stocks in the Hong Kong healthcare sector declined, with 61 stocks falling more than 4% on the day [1]. - Leading stocks such as Deqi Pharmaceuticals, BeiGene, and WuXi AppTec saw declines of 10.44%, 9.16%, and 8.69% respectively [1]. - The Hong Kong pharmaceutical index closed at 2260.95 points, down 2.60%, with a trading volume of 5.589 billion HKD, indicating a strong short-term profit-taking sentiment [1]. Group 2: Policy Impact - The adjustment coincided with a critical phase of policy implementation, including regular drug procurement, upgraded medical insurance fund supervision, and optimization of the national essential drug list [2]. - The revised Drug Administration Law Implementation Regulations will take effect on May 15, 2026, further strengthening the clinical value-oriented drug research and evaluation [2]. - Despite the policy changes, there is optimism about the potential for a diversified payment system in the healthcare industry, driven by policy dividends and the iteration of commercial health insurance products [2]. Group 3: Company Performance and Outlook - The performance window for leading companies is approaching, contributing to market cautiousness, with BeiGene set to release its financial report after the market close on February 26 [2]. - BeiGene reported a net profit of 1.422 billion CNY for the year, marking a turnaround from losses [2]. - Market experts believe that the recent adjustments do not signify a reversal of long-term industry trends but rather a recalibration of valuations in response to policy transitions [3]. Group 4: Investment Sentiment - Recent southbound capital inflows into the pharmaceutical sector have been weaker compared to technology and energy sectors, indicating a shift in capital allocation [3]. - Industry experts suggest that while short-term policies may disrupt profit expectations, they will ultimately benefit the industry's competitive landscape, allowing leading companies to strengthen their positions through R&D and compliance advantages [3]. - The current market pricing logic is shifting from merely valuing pipeline reserves to a comprehensive assessment of R&D capabilities, commercialization abilities, and compliance [3].